Sol-Gel Technologies secures $16 million for clinical trials, advancing SGT-610 for Gorlin syndrome and extending cash runway to 2027. Sol-Gel Technologies, Ltd. has announced a product purchase ...
Just because a business does not make any money, does not mean that the stock will go down. For example, Sol-Gel Technologies (NASDAQ:SLGL) shareholders have done very well over the last year, with ...
NESS ZIONA, Israel, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. , a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical ...
Sol-Gel (SLGL) intends to pursue high-frequency BCC as an additional indication for its lead drug candidate SGT-610, which, if approved, could at least double the drug’s commercial potential In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results